Cn117534672a refers to a patent application related to leniolisib [1]. This patent application appears in Google Patents searches concerning the drug leniolisib [1].
What is Leniolisib?
Leniolisib is a medication approved for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [2][3]. APDS is a rare primary immunodeficiency [2]. Leniolisib works by inhibiting the PI3Kδ pathway, which is overactive in APDS [3].
When does leniolisib's patent expire?
Information regarding the specific expiration date of patents for leniolisib, including those related to Cn117534672a, can be found through specialized patent tracking resources [4]. DrugPatentWatch.com offers such services to track patent statuses and expiry dates [4].
What is the significance of patent application Cn117534672a?
The patent application Cn117534672a is one of several intellectual property filings associated with leniolisib [1]. Such applications protect the composition of matter, manufacturing processes, or methods of use for the drug, which is crucial for the developing company's market exclusivity [5].
How does leniolisib work to treat APDS?
Leniolisib targets the PI3Kδ enzyme, which plays a key role in the signaling pathways of immune cells [3]. In APDS, this enzyme is constitutively active, leading to abnormal immune cell function and symptoms like recurrent infections, lymphoproliferation, and autoimmune complications [3]. By inhibiting PI3Kδ, leniolisib helps to restore normal immune cell function [3].
Where can I find more information about leniolisib patents?
Detailed patent information, including application numbers like Cn117534672a and their associated filings, can be accessed through patent databases such as Google Patents and specialized pharmaceutical patent tracking websites like DrugPatentWatch.com [1][4].
What are the clinical indications for leniolisib?
Leniolisib is indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [2].
Sources
1. "Cn117534672a leniolisib google patents". Google Patents. Accessed October 26, 2023.
2. "Leniolisib". National Library of Medicine. Accessed October 26, 2023.
3. "FDA Approves First Treatment for APDS". National Organization for Rare Disorders. Accessed October 26, 2023.
4. DrugPatentWatch.com. Accessed October 26, 2023.
5. "Patent Law Basics". World Intellectual Property Organization. Accessed October 26, 2023.